| Code | 2866E | ||||||||||
| MA number | 21/0029/23-S | ||||||||||
| Product Form: | sol inf 1x20 ml/200 mg (liek.inj.skl.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Fresenius Kabi s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 26.01.2023 |
| Validity: | 26.01.2028 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Lacosamide Fresenius Kabi 10 mg_ml_02.2024.pdf
|
| SPC: |
SPC_Lacosamide Fresenius Kabi_02.2024.pdf
|
| Safety feature | Yes |
| Data update: | 16.02.2024 |
